AUS
NZ
UK
CA
USA
IND
Healthcare
Actinogen Secures $9M R&D Rebate to Advance Alzheimer’s Therapy Trial
November 12, 2024 03:07 PM AEDT| By Team Kalkine MediaHighlights,Actinogen,Medical receives a $9 million R&D tax rebate.,Funds support Alzheimer’s therapy trial with 220 participants.,Financial backing ensures operations through mid-2026.,Actinogen Medical Ltd (ASX:ACW) has recently received a substanti...
Recce Pharmaceuticals Advances in Antibiotic Resistance with Trial Approval
November 11, 2024 06:57 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals receives ethics approval for Phase 3 clinical trial in Indonesia.,Company advances towards addressing antibiotic resistance with RECCE 327.,Indonesian clinical trial aims to combat diabetic foot infections.,Recce Phar...
Recce Pharmaceuticals Advances to Phase 3 Trial for Diabetic Foot Infection Treatment in Indonesia
November 11, 2024 04:01 PM AEDT| By Team Kalkine MediaHighlights,Ethics Approval for Phase 3 Trial,: Recce Pharmaceuticals received approval to initiate a large-scale Phase 3 trial in Indonesia for its RECCE® 327 (R327G) topical gel targeting diabetic foot infections.,300-Patient Study Begins in Decembe...
Recce Pharmaceuticals (ASX:RCE) Secures Phase 3 Trial Approval in Indonesia
November 11, 2024 12:56 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals secures ethics approval for Phase 3 trial of R327G in Indonesia.,Trial targets diabetic foot infections with,commercialisation,aimed for 2026.,Bilateral support from Australia and Indonesia enhances trial’s impact in...
Cleanspace Holdings (ASX:CSX) Faces Revenue Slowdown Amid Market Hurdles
November 11, 2024 11:19 AM AEDT| By Team Kalkine MediaHighlights,Cleanspace,shares dip on missed revenue expectations.,Year-to-date revenue growth,remains,flat.,Profitability improves despite minor EBITDA loss.,Cleanspace Holdings (ASX:CSX), a respiratory protection manufacturer, has faced a significant...
Three ASX 200 Stocks Propel Market Gains This Week
November 08, 2024 03:14 PM AEDT| By Team Kalkine MediaHighlights:,Neuren Pharmaceuticals Leads the Week: Neuren Pharmaceuticals (ASX:NEU) saw a 33.8% increase in its share price following positive updates and a significant lump-sum payment.,Sigma Healthcare's Strong Performance: Sigma Healthcare (ASX:SI...
ResMed (ASX: RMD) Shares Evaluated for Future Growth Prospects
November 08, 2024 03:02 PM AEDT| By Team Kalkine MediaHighlights:,ResMed's Strong Financial Performance: A reported 13.6% compound annual growth rate (CAGR) in revenue over the last three years and a 29.1% CAGR in profit.,Debt-Free Capital Structure: The company has a net cash position of $624 million,...
Neuren Pharmaceuticals Shares Surge on Strong Sales
November 08, 2024 01:29 PM AEDT| By Team Kalkine MediaHighlights,Neuren,Pharmaceuticals sees a 13.2% share price increase.,The company reports US sales of its,Daybue,drug surpassing $250 million in the first nine months.,Full-year 2024 income forecasted to range between $216 million and $218 million.,Ne...
Imugene (ASX:IMU) Expands Azer-cel CAR T-cell Lymphoma Trial in Australia
November 08, 2024 12:54 PM AEDT| By Team Kalkine MediaHighlights,Imugene,launches Australian site for,azer,-cel CAR T-cell therapy trial,.,Sydney’s Royal Prince Alfred Hospital to lead DLBCL patient recruitment,.,New phase targets better access and outcomes for lymphoma patients.,Imugene Ltd (ASX:IMU) h...
Mayne Pharma (ASX: MYX) Gains Momentum Amid Strategic Interest Exploration
November 08, 2024 11:35 AM AEDT| By Team Kalkine MediaHighlights,Mayne Pharma shares surge following confirmation of strategic interest.,Jefferies Australia exploring prospective buyers for the company.,Mayne Pharma’s valuation efforts aim to maximize shareholder value.,Mayne Pharma Group Limited (ASX:...
Sigma Healthcare Has Led the Top Gainers as the S&P/ASX 200 Sees a Modest Rise
November 07, 2024 04:44 PM AEDT| By Team Kalkine MediaHighlights:,Sigma Healthcare (ASX) Surges Following Merger Approval,Neuren Pharmaceuticals (ASX) Gains Amid Growing Optimism in Neurological Treatments,Sectors Show Mixed Performance as Market Faces Volatility,The S&P/ASX 200 index saw a modest incre...
Neuren’s ‘Willy Wonka’ Voucher Has Been Revalued at US$50 Million
November 07, 2024 04:34 PM AEDT| By Team Kalkine MediaHighlights:,Neuren Pharmaceuticals (ASX) benefits from a significant windfall through the sale of a US FDA Priority Review Voucher (PRV).,Sigma Healthcare (ASX) and Chemist Warehouse’s merger passes regulatory scrutiny, with no major competition conc...
ACCC Approval of Sigma-Chemist Warehouse Merger Sparks Market Interest
November 07, 2024 03:57 PM AEDT| By Team Kalkine MediaHighlights,ACCC grants approval for Sigma Healthcare and Chemist Warehouse merger.,Court-enforceable undertaking ensures fair market competition.,Chemist Warehouse to enter ASX without an IPO fanfare.,The Australian Competition and Consumer Commissio...
Amplia Therapeutics Successfully Raises $13 Million via Share Allotment
November 07, 2024 03:41 PM AEDT| By Team Kalkine MediaHighlights:,Amplia Therapeutics Ltd. successfully raised $13 million through an institutional placement.,Over 67 million shares were allotted at a price of $0.115 each, strengthening the company’s financial position.,The company is advancing its rese...
Sigma (ASX:SIG) Shares Rise 30% After Chemist Warehouse Merger Gets ACCC Green Light
November 07, 2024 03:02 PM AEDT| By Team Kalkine MediaHighlights:,Sigma Healthcare's share price surged 31% following the approval of its merger with Chemist Warehouse.,The Australian Competition & Consumer Commission (ACCC) cleared the merger with specific conditions, including a court-enforceable unde...
Sigma Healthcare Moves Forward with Merger as ACCC Approves Deal with Chemist Warehouse
November 07, 2024 02:26 PM AEDT| By Team Kalkine MediaHighlights,The Australian Competition and Consumer Commission (ACCC) approves Sigma Healthcare’s merger with Chemist Warehouse Group (CWG), with conditions.,Sigma to acquire CWG for shares and $700m in cash, resulting in Chemist Warehouse shareholder...
Neuren’s FY2024: Revenue Surge from Tax Credits & Drug Partnerships
November 07, 2024 11:23 AM AEDT| By Team Kalkine MediaHighlights,Neuren,forecasts FY2024 income in the range of $216 million to $218 million.,Expected $17 million tax credit due to recognized New Zealand tax losses.,Acadia Pharmaceuticals projects $340-$350 million in sales for their partnered neurologi...
Sigma Healthcare Secures ACCC Approval for Chemist Warehouse Merger
November 07, 2024 11:04 AM AEDT| By Team Kalkine MediaHighlights,ACCC grants approval for Sigma Healthcare’s merger with Chemist Warehouse.,Sigma commits to competitive practices and pharmacy service obligations.,Reverse acquisition places Chemist Warehouse shareholders with a major stake.,Sigma Healthc...
Key ASX Penny Stocks for November 2024 Identified
November 06, 2024 06:56 PM AEDT| By Team Kalkine MediaHighlights:,The ASX200 is showing signs of upward momentum, influenced by positive movements on Wall Street and global events such as China’s National People’s Congress.,Penny stocks on the ASX continue to offer high-growth opportunities, particularl...
Alterity’s 'Iron Overload in Brain' Thesis Endorsed by Prominent Publication
November 06, 2024 06:21 PM AEDT| By Team Kalkine MediaHighlights:,Alterity Therapeutics (ASX) receives peer-reviewed recognition for its neurological drug candidate ATH434 in,Metallomics,.,Respiri (ASX) poised to benefit from new US reimbursement rules for remote patient monitoring, boosting market pote...
Advertise your brand on Kalkine Media